Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04923126 · ClinicalTrials.gov registry record · Phase 1
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
A Phase 1 study of Low Grade Glioma and Recurrent Low Grade Glioma, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
- 1
- Study location
NCT04923126 is a Phase 1 study of Low Grade Glioma and Recurrent Low Grade Glioma that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 132 participants, above the 108-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (22% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04923126, a Phase 1 study of Low Grade Glioma and Recurrent Low Grade Glioma, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
Conditions Studied
Interventions
- DRUG Mirdametinib
Study Locations (1)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2021-06-21 |
| Est. Completion | 2031-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04923126
The ClinicalTrials.gov registry entry for NCT04923126 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 23 other Low Grade Glioma trials with a reported enrollment target (22% higher). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Low Grade Glioma appearing as the primary indexed condition, and to 1 intervention - of which Mirdametinib is the first listed.
NCT04923126 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT04923126 about?
NCT04923126 is a clinical study titled "SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma". This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
What is the current status of trial NCT04923126?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2021-06-21. Estimated completion is 2031-06.
What conditions does trial NCT04923126 study?
This clinical trial studies the following conditions: Low Grade Glioma, Recurrent Low Grade Glioma, Progressive Low-Grade Glioma.
What interventions are being tested in trial NCT04923126?
The interventions under investigation include: Mirdametinib (DRUG).
Who is sponsoring clinical trial NCT04923126?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04923126 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
-
A Study of Avutometinib for People With Solid Tumor Cancers
RECRUITING · Phase 1
-
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
RECRUITING · Phase 1
-
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.